Abstract
This chapter introduces diabetes, an ancient disease that continues to affect diverse populations in modern times and the various types of diabetes are discussed. Insulin has been traditionally used to treat the disease. However, the one significant limitation of using insulin is that an insulin overdose is the single most potent cause of life-threatening hypoglycemia. Glucagon-like Peptide-1 (GLP1) is a 30 amino acid peptide that stimulates insulin only when the blood glucose level is high, hence the risk of hypoglycemia is substantially minimized. However, the biggest problem in the therapeutic use of GLP-1 is its extremely short half-life in plasma (~2 min). In the last subsection of this chapter, the utility of prodrugs is discussed in general and how GLP-1 based prodrugs could appropriately extend the biological half life and broaden the therapeutic index of GLP.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Majumdar SK (2001) Bull Indian Inst His Med Hyderabad 31(1): 57–70
Pendergrass M (2007) Nat Endocrinol Metabol 3(1):1
Cryer PE (2007) Nat Endocrinol Metabol 3(1):4–5
Onkamo P et al (2000) Diabetologia 43(10):1334–1336
Kishiyama CM, Chase H, Barker JM (2006) Rev Endocr Metab Disord 7(3):215–224
The Diabetes Control and Complications Trial Research Group (1998) Ann Intern Med 128(7):517–523
Cavaghan MK et al (2000) J Clin Investig 106:329–333
Sadikot SM Jaslok Hospital and Research Centre, Mumbai http://diabetesindia.com/
United Kingdom Prospective Diabetes Study (1995) Diabetes 44:1249–1258
Banting FG et al (1922) Can Med Assoc J 12:141–146
Banting FG, Best CHJ (1922) J Lab Clin Med 7:464–472
Sanger F (1959) Science 129(3359):1340–1344
Lepore M et al (2000) Diabetes 49(12):2142–2148
De León DD, Stanley CA (2007) Nat Clin Pract Endocrinol Metab 3:57–68
The Diabetes Control and Complications Trial Research Group (1993) The. N Engl J Med 329(14):977–986
Nicholas GA, Gomez-Caminero A (2007) Diab, Obes Metab 9(1):96–102
Johnston LW, Weinstock RS (2006) Mayo Clin Proc 81(12):1615–1620
Nauck MA et al (2002) J Clin Endocrinol & Metab 87(3):1239–1246
Schmidt WE, Siegel EG, Creutzfeldt W (1985) Diabetologia 28(9):704–707
Green BD et al (2003) Biol Chem 384:1543–1551
Holst JJ (1999) Trends Endocrinol Metab 10:229–234
McCormack JG (2006) Biochem Soc Trans 34:238–242
Orskov C et al (1996) World J Gastroenterol 31:665–670
Daniel J et al (2006) Lancet 368(9548):1696–1705
Giorgino F et al (2006) Diab Res Clin Pract 74(2):S152–S155
Butler AE et al (2003) Diabetes 52:102–110
Nauck M et al (1986) Diabetologia 29:46–52
Drucker DJ et al (1987) Proc Natl Acad Sci 84:3434–3438
Holz GG et al (1999) J Biol Chem 274:14147–14156
Gromada J et al (1998) Pflugers Arch 435:583–594
Weir GC et al (1989) Diabetes 38:338–342
Hui H et al (2005) Diab/Metab Res Rev 21:313–331
Rabenhoj L et al (1994) Diabetes 43(4):535–539
Adelhorst K et al (1994) J Biol Chem 269(9):6275–6278
Larsen J et al (2001) Diab Care 24:1416–1421
Ørskov C, Wettergren A, Holst JJ (1993) Diabetes 42:658–661
Deacon CF et al (1995) J Clin Endocrinol Metab 80:952–957
Knudsen LB, Pridal L (1996) Eur J Pharmacol 318:429–435
Holst JJ, Deacon CF (1998) Diabetes 47(11):1663–1670
Åhren B et al (2004) J Clin Endocrinol Metab 89:2078–2084
Stuart AR, Gulve EA, Minghan W (2004) Chem Rev 104(3):1255–1282
Thorens B et al (1993) Diabetes 42(11):1678–1682
Eng J et al (1992) J Biol Chem 267(11):7402–7405
Kolterman OG et al (2005) Am J Health Syst Pharm 62:173–181
Kendall DM et al (2005) Diab Care 28:1083–1091
Knudsen LB et al (2000) J Med Chem 43:1664–1669
Bjerre KL et al (2005) Diabetes 52(1):321–322
Deacon CF (2004) Diabetes 53:2181–2189
IUPAC Pure & Applied Chemistry (1998) 70(5):1129–1143
Albert A (1958) Nature 182:421–423
Jiunn HL, Lu AYH (1997) Pharmacology Rev 49:403–449
Stañczak A, Ferra A (2006) Pharmacol Rep 58:599–613
Beaumont K et al (2003) Curr Drug Metab 4:461–485
Humphrey MJ, Ringrose PS (1986) Drug Metab Rev 17:283–310
Saffran M et al (1988) J Pharm Sci 77:33–38
Lee SH et al (2005) Bioconjug Chem 16:377–382
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2013 The Author(s)
About this chapter
Cite this chapter
De, A. (2013). Introduction. In: Application of Peptide-Based Prodrug Chemistry in Drug Development. SpringerBriefs in Pharmaceutical Science & Drug Development. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4875-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4875-4_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4874-7
Online ISBN: 978-1-4614-4875-4
eBook Packages: MedicineMedicine (R0)